ArticleFrontiers in immunology2026
GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPARγ pathway to drive M2 macrophage polarization.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regulation of immune tolerance in hepatocellular carcinoma by liver diseases: a review.Infectious agents and cancer · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a major threat to human health worldwide. Its suboptimal responses to current therapies are largely attributable to the immunosuppressive tumor microenvironment (TME) that dampens the efficiency of available treatments. Although metabolic reprogramming is regarded as a hallmark of HCC, the exact role of peroxisomal metabolism in immune evasion is poorly understood. By integrating bioinformatic analysis of TCGA-LIHC datasets and peroxisomal gene profiling, glyceronephosphate O-acyltransferase (GNPAT) was identified as a regulator of HCC pathogenesis. GNPAT was highly expressed in malignant tissues and positively associated with poor clinical outcomes and immunosuppressive cellular infiltration types. Functional experiments showed that GNPAT facilitated the proliferation, migration, and resistance to apoptosis of HCC cells in an autocrine manner via enhancing plasmalogen synthesis and downstream PPAR pathway activation. Interestingly, overexpression of GNPAT in HCC cells polarized macrophages to the M2-like phenotype and reinforced immunosuppressive TME through the plasmalogen-PPAR axis. An unrecognized mode of immunometabolic crosstalk mediated by peroxisomal metabolism in HCC was thereby revealed, providing a preclinical rationale and mechanistic basis for future exploration of GNPAT inhibition as a potential therapeutic strategy to antagonize immunosuppression and enhance antitumor immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.